



## BÖLÜM 9

### MİDE HASTALIKLARINDA PET-BT VE PET-MR

Ensar TÜRKO<sup>1</sup>

#### 1. GİRİŞ

Pozitron Emisyon Tomografisi-Bilgisayarlı Tomografi (PET-BT) ve Pozitron Emisyon Tomografisi-Manyetik Rezonans (PET-MR) görüntüleme son yıllarda teknolojinin ve medikal bilgi birikiminin artması ışığında kullanımı giderek artmaktadır. Yalnız mide hastalıklarında kullanım yeri kısıtlı olup; genellikle mide tümörlerinde ve primer gastrik lenfomada tedavi öncesi ve sonrasında hasta yaklaşımının planlanmasında kullanılmaktadır.

#### 2. PET-BT

Pozitron emisyon tomografisi (PET) çekimi sırasında aynı anda, aynı cihazla hem PET hem BT çekilir. Şeker türevi olan ve pozitron ışıması yapan, flor-18 ile işaretlenmiş deoksiglukoz molekülü FDG (18 flor-2-deoksi-D glukoz) damar yolundan verilerek inceleme yapılmaktadır. Bu molekül gama ışını yaymakta olup; yayılan ışınlar bilgisayarlı tomografi ile saptanıp kesitsel görüntülemeye çevrilmektedir.

PET görüntüleri anatomik olarak BT görüntüleri kadar yüksek çözünürlükte olmamakla birlikte, yapısal değişikliğe uğramamış metabolik farklılıkları saptama-

<sup>1</sup> Uzm. Dr., Sivas Şarkışla Devlet Hastanesi Radyoloji Kliniği, ensarturko@hotmail.com

**KAYNAKLAR**

1. Siewert JR, Böttcher K, Stein HJ, et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. *Ann Surg*. 1998;228(4):449.
2. Washington K. of the AJCC cancer staging manual: stomach. *Ann Surg Oncol* 2010;17(12):3077-9.
3. Juweid ME, & Cheson, BD. Positron-emission tomography and assessment of cancer therapy. *N Engl J Med*, 2006;354(5), 496-507.
4. Scott AM. Current status of positron emission tomography in oncology. *Australas Radiol*, 2002;46(2), 154-162.
5. Findlay JM, Antonowicz S, Segaran A, et al. Routinely staging gastric cancer with 18 F-FDG PET-CT detects additional metastases and predicts early recurrence and death after surgery. *Eur Radiol*, 2019;29(5), 2490-2498.
6. Stahl A, Ott K, Weber W, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. *Eur J Nucl Med Mol Imaging*, 2003;30(2), 288-295.
7. Yeung HWD, Macapinlac H, Karpel M, et al. Accuracy of FDG-PET in gastric cancer: preliminary experience. *Clin Positron Imaging*, 1998;1(4), 213-221.
8. Mochiki E, Kuwano H, Katoh H, et al. Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. *World J Surg*, 2004;28(3), 247-253.
9. Chen J, Cheong JH, Yun MJ, et al. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. *Cancer: Interdisciplinary International J Am Cancer Society*, 2005;103(11), 2383-2390.
10. Takahashi H, Ukawa K, Ohkawa N, et al. Significance of 18 F-2-deoxy-2-fluoro-glucose accumulation in the stomach on positron emission tomography. *Ann Nucl Med* 2009;23(4), 391-397.
11. Koga H, Sasaki M, Kuwabara Y, et al. An analysis of the physiological FDG uptake pattern in the stomach. *Ann Nucl Med*. 2003;17(8), 733-738.
12. Serrano OK, Love C, Goldman I, et al. The value of FDG-PET in the staging of gastric adenocarcinoma: A single institution retrospective review. *J Surg Oncol* , 2016;113(6), 640-646.
13. Smyth E, Schöder H, Strong VE, et al. A prospective evaluation of the utility of 2-deoxy-2-[18F] fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer. *Cancer*, 2012;118(22), 5481-5488.
14. Kitajima K, Nakajo M, Kaida H, et al. Present and future roles of FDG-PET/CT imaging in the management of gastrointestinal cancer: an update. *Nagoya J Med Sci* 2017;79(4), 527.
15. Gauthé M, Richard-Molard M, Cacheux W, et al. Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers. *Dig Liver Dis*, 2015;47(6), 443-454.
16. Malibari N, Hickerson M, & Lisbona, R. PET/computed tomography in the diagnosis and staging of gastric cancers. *PET Clin*, 2015;10(3), 311-326.
17. Kawanaka Y, Kitajima K, Fukushima K, et al. Added value of pretreatment 18F-FDG PET/CT for staging of advanced gastric cancer: comparison with contrast-enhanced MDCT. *Eur J Radiol*, 2016;85(5), 989-995.
18. Papageorgiou SG, Filippi VP, & Chatziioannou SN (2016). The Role of PET/CT Scan in Primary Gastric Lymphomas. In *PET/CT in Lymphomas* (pp. 251-256). Springer, Cham.

19. Treglia G, Zucca E, Sadeghi R, et al. Detection rate of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta-analysis. *Hematol Oncol*, 2015;33(3), 113-124.
20. Zelenetz AD, Gordon LI, Wierda WG, et al. Non-Hodgkin's lymphomas, version 2.2014. *J Natl Compr Canc Netw*, 2014;12(6), 916-946.
21. Albano D, Bertoli M, Ferro P, et al. 18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience. *Eur J Nucl Med Mol Imaging*, 2017;44(4), 589-597.
22. Cui J, Zhao P, Ren Z, et al. Evaluation of dual time point imaging 18F-FDG PET/CT in differentiating malignancy from benign gastric disease. *Med*, 2015;94(33).
23. Antoch G, & Bockisch A. Combined PET/MRI: a new dimension in whole-body oncology imaging? *Eur J Nucl Med Mol Imaging*, 2009;36(1), 113-120.
24. Balyasnikova S, Löfgren J, de Nijs R, et al. PET/MR in oncology: an introduction with focus on MR and future perspectives for hybrid imaging. *Am J Nucl Med Mol Imaging* 2012;2(4), 458.
25. Zaidi H, Montandon ML, & Alavi A. The clinical role of fusion imaging using PET, CT, and MR imaging. *PET Clin*, 2008;3(3), 275-291.
26. Vaska P, & Cao T (2013, January). The state of instrumentation for combined positron emission tomography and magnetic resonance imaging. In *Seminars in nuclear medicine*. WB Saunders. (Vol. 43, No. 1, pp. 11-18)
27. Yankeelov TE, Peterson TE, Abramson RG, et al. Simultaneous PET-MRI in oncology: a solution looking for a problem? *Magn Reson Imaging* 2012;30(9), 1342-1356.
28. Liu B, Ramalho M, AlObaidy M, et al. Gastrointestinal imaging-practical magnetic resonance imaging approach. *World J Radiol*, 2014;6(8), 544.
29. Giganti F, Tang L, & Baba H. Gastric cancer and imaging biomarkers: Part 1—a critical review of DW-MRI and CE-MDCT findings. *Eur Radiol*, 2019;29(4), 1743-1753.
30. Tang L, Wang XJ, Baba H, et al. Gastric cancer and image-derived quantitative parameters: Part 2—a critical review of DCE-MRI and 18 F-FDG PET/CT findings. *Eur Radiol* 2020;30(1), 247-260.
31. Paspulati RM, & Gupta A. PET/MR imaging in cancers of the gastrointestinal tract. *PET Clin*, 2016;11(4), 403-423.
32. Liu Y, Zheng D, Liu JJ, et al. Comparing PET/MRI with PET/CT for pretreatment staging of gastric cancer. *Gastroenterol Res Pract*, 2019;2019.